Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2759 • 2017 ACR/ARHP Annual Meeting
The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Massimo Radin¹, Karen Schreiber², Irene Cecchi³, Dario Roccatello⁴, Maria Jose Cuadrado⁵ and Savino Sciascia⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The antiphospholipid syndrome(APS)is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity andpersistent positivityfor antiphospholipid antibodies(aPL). The most common neurological manifestation of APS is…
Abstract Number: 2760 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Ozan Unlu¹, Danieli Andrade², Alessandra Banzato³, D. Ware Branch⁴, Paul R. Fortin⁵, Maria Gerosa⁶, Roger A. Levy⁷, Michelle Lopes⁸, Michelle Petri⁹, Ignasi Rodriguez¹⁰, Maria Tektonidou¹¹, Amaia Ugarte¹², Rohan Willis¹³, Doruk Erkan¹⁴ and , on Behalf of APS ACTION .¹⁵, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁵Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ⁶Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁷Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁸Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹⁰Rheumatology, Hospital Clinica, Barcelona, Spain, ¹¹First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ¹²Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ¹³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ¹⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁵., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 2762 • 2017 ACR/ARHP Annual Meeting
Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Mériem Belhocine¹, Laetitia Coutte², Nicolas Martin Silva³, Nathalie Morel⁴, Gaelle Guettrot-Imbert⁴, Romain Paule⁴, Michel Dreyfus⁵, Micaela Fredi⁶, Odile Souchaud-Debouverie⁷, Jean Charles Piette⁸, Veronique Le Guern⁴ and Nathalie Costedoat-Chalumeau¹, ¹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ²Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Department of Internal Medicine, University Hospital Center of Caen, Caen, France, ⁴Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁵Department of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital Center of Caen, Caen, France, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Department of Internal Medicine, Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ⁸Department of Internal Medicine, Department of Internal Medicine, University Hospital Pitié-Salpétrière, Paris, France
Background/Purpose: The antiphospholipid syndrome (APS) is defined by a combination of arterial and/or venous thrombosis, pregnancy morbidity, and persistent antiphospholipid antibodies. There is a real…
Abstract Number: 2 • 2017 ACR/ARHP Annual Meeting
Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients
Yu Zuo¹, Jennifer Fan², Ravi Sarode¹, Song Zhang², Una E. Makris¹, David Karp³ and Yu-min Shen², ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, dallas, TX, ³Rheumatology, UT Southwestern Med Ctr, Dallas, TX
Background/Purpose: The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL) in individual patients without APS clinical manifestation is challenging. Our aim is…
Abstract Number: 2763 • 2017 ACR/ARHP Annual Meeting
mTORC1 Blockade with Rapamycin and N-Acetylcysteine Reduces Anti-Phospholipid Antibody Levels in Controlled Clinical Trials of Patients with SLE
Thomas Winans¹, Ryan Kelly², Zhi-Wei Lai³, Stephen Faraone², Paul E. Phillips⁴, Katalin Banki⁵ and Andras Perl³, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY, ⁴Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, ⁵Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Anti-phospholipid antibodies (aPL) constitute a diagnostic criterion and source of morbidity, termed anti-phospholipid syndrome (APS), in patients with or without systemic lupus erythematosus (SLE).…
Abstract Number: 3 • 2017 ACR/ARHP Annual Meeting
Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry
Aurelia Luissi¹, Marina Scolnik¹, Maria Florencia Grande Ratti², Maria Lourdes Posadas Martinez² and Enrique R. Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ²Research Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ³Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Prevalence of antiphospholipid antibodies in general population has been reported in about 5%. Impact of different thrombophilias in clinical thromboembolic disease is difficult to…
Abstract Number: 2764 • 2017 ACR/ARHP Annual Meeting
Gene Expression Profile in Monocytes of Antiphospholipid Syndrome Patients Reveals Novel Altered Genes and Pathways Involved in the Pathophysiology of the Disease
Patricia Ruiz-Limon¹, Carlos Perez-Sanchez², Maria Ángeles Aguirre Zamorano², Irene Cecchi³, Nuria Barbarroja², Yolanda Jiménez-Gómez², Ivan Arias de la Rosa¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui⁴, Eduardo Collantes-Estévez², Maria Jose Cuadrado⁵ and Chary Lopez-Pedrera², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Monocytes are key players involved in the development of several autoimmune disease due to their capacity to modulate lipid metabolism, secrete inflammatory cytokines, chemokines,…
Abstract Number: 5 • 2017 ACR/ARHP Annual Meeting
Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients
Savino Sciascia¹, Massimo Radin², Giovanni Sanna³, Irene Cecchi⁴, Dario Roccatello⁵ and Maria Laura Bertolaccini⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, London, United Kingdom, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, United Kingdom, London, United Kingdom
Background/Purpose: Recently, our group conceived a risk score for clinical manifestations of APS [the global APS score or GAPSS] that takes into account the combination…
Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Dana Tegzova¹, Katerina Andelova², Iva Kucerova², Vera Vlasakova³, Stejskal Jan⁴, Putova Ivana⁵, Marta Olejarova⁶ and Ctibor Dostál⁷, ¹Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ²Institute of Mother and Child Care, Prague, Prague, Czech Republic, ³Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, ⁴1st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, ⁶Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…
Abstract Number: 7 • 2017 ACR/ARHP Annual Meeting
Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The lupus anticoagulant (LAC) is individually the antiphospholipid antibody (aPL) most associated with thrombotic risk in both primary and secondary APS. Anticardiolipin (aCL) and…
Abstract Number: 9 • 2017 ACR/ARHP Annual Meeting
Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome
Hironari Hanaoka¹, Tomofumi Kiyokawa¹, Harunobu Iida¹, Yukiko Takakuwa¹, Takahiro Okazaki², Hidehiro Yamada³, Shoichi Ozaki⁴ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ⁴Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is…
Abstract Number: 10 • 2017 ACR/ARHP Annual Meeting
Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score
Flavio Signorelli¹, Gustavo G M Balbi², Roger A. Levy² and Savino Sciascia³, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The adjusted Global AntiPhospholipid Syndrome Score (aGAPSS) was described as a tool to estimate the risk of thromboses in patients with APS. The aim…
Abstract Number: 11 • 2017 ACR/ARHP Annual Meeting
Possible Therapeutics for Antiphospholipid Antibody Related Thrombocytopenia: A Systemic Review and Meta-Analysis
Nobuya Abe¹, Kenji Oku¹, Olga Amengual¹, Yuichiro Fujieda¹, Masaru Kato¹, Toshiyuki Bohgaki¹, Shinsuke Yasuda¹, Rintaro Mori², Eriko Morishita³, Katsue Suzuki-Inoue⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan, ³Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ⁴Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Background/Purpose: Despite the pro-thrombotic nature of antiphospholipid antibodies (aPL), thrombocytopenia is frequently observed in patients with antiphospholipid syndrome (APS) or in non-APS patients with aPL.…
Abstract Number: 15 • 2017 ACR/ARHP Annual Meeting
Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome
Kimberly Legault¹, Christopher Hillis¹, Cindy Yeung¹, Elie Akl², Marc Carrier³, Ricard Cervera⁴, Mark Crowther¹, Francesco Dentali⁵, Doruk Erkan⁶, Gerard Espinosa⁷, Munther A Khamashta⁸, Joerg Meerpohl⁹, Karen Moffatt¹⁰, Sarah O'Brien¹¹, Vittorio Pengo¹², Jacob Rand¹³, Ignasi Rodriguez¹⁴, Lisa Thom¹⁵, Holger Schunemann¹ and Alfonso Iorio¹, ¹McMaster University, Hamilton, ON, Canada, ²American University of Beirut, Beirut, Lebanon, ³University of Ottawa, Ottawa, ON, Canada, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Insubria University, Insubria, Italy, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada, ¹¹Nationwide Children's, Columbus, OH, ¹²Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ¹³NY Presbyterian Hospital, New York, NY, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵None (patient representative), Oxford, United Kingdom
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS), a rare disease, is characterized by the rapid onset of widespread thrombosis associated with multi-organ failure in patients meeting the…
Abstract Number: 16 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies in Primary Antiphospholipid Syndrome
Paola Bermudez-Bermejo¹, Gabriela Hernandez-Molina², Diego Hernández-Ramírez³, Victor Zamora-Legoff², Elizabeth Olivares-Martínez³, Antonio R. Cabral⁴ and Carlos Núñez-Álvarez⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición SZ, mexico city, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico
Background/Purpose: Several studies have showed conflicting results regarding the presence and meaning of anti-phosphatidylserine/prothrombin (aPS/PT). However aPS/PT antibodies seem to be a risk factor for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].